Q4154 Biovance (HCPCS) Reimbursement & Policy | OpenPayer

Summary & Overview

HCPCS Q4154: Biovance Wound Matrix, per Square Centimeter

HCPCS Level II code Q4154 designates Biovance supplied and billed per square centimeter as an add-on item, reported separately in addition to a primary procedure. Biovance is a biologic wound matrix used in surgical and advanced wound care to support healing; the code enables item-level reporting for products that supplement procedural services. Nationally, accurate use of Q4154 affects claims clarity, product utilization tracking, and payer coverage determinations for biologic wound care.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers typically approach add-on product billing, common coverage considerations, and claims processing practices relevant to per-unit (per cm2) biologic products.

Readers will learn the clinical context for using Biovance as an adjunct to primary wound procedures, expected sites of service, and the administrative implications of per-square-centimeter billing. The report provides benchmarks for coding practice, summarizes policy themes seen across national payers, and highlights documentation elements that are commonly reviewed in adjudication. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ4154HCPCS Level IIBiovancewound carebiologic graftadd-on codeoutpatient surgerymedical billingclaims coding

Billing Code Overview

HCPCS Level II code Q4154 represents Biovance, billed per square centimeter as an add-on product to be listed separately in addition to the primary procedure. The code is used to report the application of Biovance wound matrix when it is supplied in addition to a primary surgical or wound-care procedure.

Service type: Wound care product / biologic graft application

Typical site of service: Hospital outpatient departments, ambulatory surgery centers, wound care clinics, and other outpatient settings where surgical or procedural wound management occurs

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with a full-thickness or complex partial-thickness dermal wound (for example, a non-healing surgical wound, traumatic soft-tissue loss, or chronic ulceration) requiring application of a biologic skin allograft to promote wound closure. The procedure is performed in an outpatient wound care clinic, ambulatory surgery center, or hospital outpatient department. The clinical workflow includes wound assessment and debridement, measurement of wound surface area in square centimeters, preparation of the wound bed (hemostasis and irrigation), selection and thawing/preparation of the Biovance product, application of the graft to the wound surface, fixation (sutures, staples, adhesive dressings or negative-pressure wound therapy as indicated), and documentation of graft area and number of square centimeters applied. The service is billed as an add-on per square centimeter using Q4154 in addition to a primary wound management or debridement procedure code. Typical patient monitoring includes dressing changes, infection surveillance, and follow-up visits to assess graft take and wound healing.

Coding Specifications

Modifier	Description	When to Use
`59`	Distinct procedural service	Data not available in the input.

HCPCS Q5159: Denosumab-dssb (ospomyv/xbryk) Injection, 1 mg

HCPCS-Q4230-COGENEX-FLOWABLE-AMNION-0-5CC

HCPCS Level II Q4230: Cogenex Flowable Amnion, 0.5 cc

HCPCS-Q0138-FERUMOXYTOL-INJECTION-IRON-DEFICIENCY-ANEMIA-NON-ESRD

HCPCS Q0138: Ferumoxytol Injection for Iron Deficiency Anemia, Non-ESRD

HCPCS-Q4431-PMA-SKIN-SUBSTITUTE-ADD-ON

HCPCS Q4431: PMA Skin Substitute Product, Add-On

HCPCS-Q5118-BEVACIZUMAB-BVZR-ZIRABEV-10MG-INJECTION

HCPCS Q5118: Bevacizumab-bvzr (Zirabev) 10 mg Injection

HCPCS-LEVEL-II-Q4256-AREA-BASED-PROCEDURAL-ADD-ON-PER-SQ-CM

HCPCS Level II Q4256: Area-Based Procedural Add-On, Per sq cm

HCPCS-Q4028-PEDIATRIC-HIP-SPICA-FIBERGLASS-CAST-SUPPLIES

HCPCS Level II Q4028: Pediatric Hip Spica Fiberglass Cast Supplies

HCPCS-Q9977-COMPOUNDED-DRUG-NOT-OTHERWISE-CLASSIFIED

HCPCS Q9977: Compounded Drug, Not Otherwise Classified

HCPCS-Q4277-WOUNDPLUS-MEMBRANE-E-GRAFT-PER-SQ-CM

HCPCS Level II Q4277: Woundplus Membrane or E-Graft, per sq cm

HCPCS-Q4387-NEOTHELIUM-PER-SQ-CM-ADD-ON

HCPCS Level II Q4387: Neothelium per Square Centimeter (Add-on)

Showing 1–10 of 629

22

Taxonomy Code	Specialty	Notes
`364S00000X`	Wound Care Specialist	Clinicians who frequently perform biologic graft applications in outpatient settings.
`207L00000X`	General Surgery	Surgeons who manage complex wounds and apply biologic skin substitutes.
`208000000X`	Family Medicine	Primary care physicians in outpatient clinics who manage chronic wounds and refer or perform applications.
`163W00000X`	Plastic Surgery	Plastic surgeons performing reconstructive procedures using biologic grafts.
`367500000X`	Podiatry	Podiatrists treating lower-extremity ulcers that may use skin allografts.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L97.421`	Non-pressure chronic ulcer of right ankle with necrosis of muscle	Chronic lower-extremity ulcers are common indications for biologic skin allografts to promote healing.
`L97.929`	Non-pressure chronic ulcer of unspecified lower leg with unspecified severity	General lower-extremity chronic wounds that may benefit from grafting.
`L89.153`	Pressure ulcer of sacral region, stage 3	Pressure injuries with full-thickness tissue loss often require biologic grafts as part of advanced wound care.
`S81.811A`	Complex open wound of right knee, initial encounter	Traumatic soft-tissue loss after injury may be treated with a biologic allograft.
`T79.A11A`	Traumatic compartment syndrome of right lower leg, initial encounter	Complex soft-tissue defects following ischemic or traumatic injury can need grafting.
`E11.621`	Type 2 diabetes mellitus with foot ulcer	Diabetic foot ulcers are a frequent clinical scenario for application of skin allografts.
`K11.3`	Chronic ulcer of oral mucosa	Selected mucosal defects may be treated with specialized biologic grafts depending on product labeling.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`11042`	Debridement, subcutaneous tissue, first 20 sq cm or less	Often performed immediately before application of a biologic graft to remove nonviable tissue.
`11043`	Debridement, muscle and/or fascia, first 20 sq cm or less	Performed when deeper tissue debridement is required prior to graft placement.
`15271`	Application of skin substitute graft to trunk, arms, legs; first 100 sq cm or less	A primary procedure code that may be reported in conjunction with or in lieu of coding supplies; `Q4154` is billed as an add-on per sq cm for a specific Biovance product.
`15002`	Skin substitute graft application to face, scalp, eyelids, mouth, neck, ears; first 30 sq cm or less	Applied for facial or delicate area wounds where biologic grafts are used; used in the procedural workflow when site-specific coding is needed.
`97602`	Mechanical debridement (eg, high pressure waterjet) with or without suction, without anesthesia; initial visit	May be used as an adjunct or prior debridement method before graft application.

OpenPayer